Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2162)	1/17/2008 10:48:20 AM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

MON says that its Biotech is just beginning.<g> It told its shareholders yesterday that record profits in 2007 are just the beginning, with growing acceptance of genetically engineered crops expected to have new business opportunities for next decades. But the stock continued its drop from yesterday, starting today with a DG, going through the support at the $110 level as it seems to want to test its next support at $100. <g> The stock is down 11.11%, (albeit that could be a lucky number.<g>) with volume now getting close to 6M & above its ADV. bigcharts.marketwatch.com MON wans to unlock the power of genetically engineering plants. In the 90s its blockbuster products were Roundup Ready crops, which contained a gene that made them resistant to its herbicide, which made it easier, and cheaper, for farmers to control weeds. But now MON says that by 2010 it plans to release a strain of corn with eight engineered traits. In spite of its high PE, with its +CF around $3, its 4Qs of better revenues & its better EE for 2008 & 2009, it seems that MON will be able to resume its UT that remains intact since it started in 2004 from the $15 level.<g> bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (2162)	1/17/2008 11:38:17 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

INGN was up 3.37% & is still trying to stay above the $3 level.<g> Volume has remained low around 0.25x its ADV bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (2162)	12/17/2010 12:01:48 PM
From: Jibacoa	Respond to of 3722

ITMN is still up 130% <g> bigcharts.marketwatch.com Today it announced additions to its senior leadership team to prepare for the commercialization of Esbriet in Europe. Its MAA for Esbriet received a positive CHMP opinion that is now awaiting ratification by the European Commission. They said: "We will continue to move quickly to prepare to launch the first approved therapy in Europe in adults for the treatment of mild to moderate Idiopathic Pulmonary Fibrosis".<g> The ACTAY is 18 But maybe the stock could get back to test the $50 level.<g> bigcharts.marketwatch.com Bernard